Michael E. Kopach
Eli Lilly and Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael E. Kopach.
Green Chemistry | 2013
Asha Kadam; Mylinh Nguyen; Michael E. Kopach; Paul G. Richardson; Fabrice Gallou; Zhao-Kui Wan; Wei Zhang
The solvent effect on the Grignard reaction of benzyl, aryl and heteroaromatic substrates has been systematically evaluated based on reaction efficiency, ease of subsequent work-up, safety and greenness. 2-Methyltetrahydrofuran (2-MeTHF), which can be derived from renewable resources, had at least an equal if not a superior overall process most notably in suppressing the Wurtz coupling by-product from the benzyl Grignard reactions. It is therefore a recommended alternative solvent to Et2O and THF for the preparation of most Grignard reagents and their subsequent reactions.
Green Chemistry | 2017
Frank Roschangar; Juan Colberg; Peter J. Dunn; Fabrice Gallou; John D. Hayler; Stefan G. Koenig; Michael E. Kopach; David K. Leahy; Ingrid Mergelsberg; John L. Tucker; Roger A. Sheldon; Chris H. Senanayake
Green and sustainable drug manufacturing go hand in hand with forward-looking visions seeking to balance the long-term sustainability of business, society, and the environment. However, a lack of harmonization among available metrics has inhibited opportunities for green chemistry in industry. Moreover, inconsistent starting points for analysis and neglected complexities for diverse manufacturing processes have made developing objective goals a challenge. Herein we put forward a practical strategy to overcome these barriers using data from in-depth analysis of 46 drug manufacturing processes from nine large pharmaceutical firms, and propose the Green Aspiration Level as metric of choice to enable the critically needed consistency in smart green manufacturing goals. In addition, we quantify the importance of green chemistry in the often overlooked, yet enormously impactful, outsourced portion of the supply chain, and introduce the Green Scorecard as a value added sustainability communication tool.
Green Chemistry | 2012
Michael E. Kopach; Dilwyn J. Roberts; Martin D. Johnson; Jennifer McClary Groh; Jonathan J. Adler; John P. Schafer; Michael E. Kobierski; William George Trankle
A key pharmaceutical intermediate (1) for production of edivoxetine·HCl was prepared in >99% ee via a continuous Barbier reaction, which improves the greenness of the process relative to a traditional Grignard batch process. The Barbier flow process was run optimally by Eli Lilly and Company in a series of continuous stirred tank reactors (CSTR) where residence times, solvent composition, stoichiometry, and operations temperature were optimized to produce 12 g h−1 crude ketone 6 with 98% ee and 88% in situ yield for 47 hours total flow time. Continuous salt formation and isolation of intermediate 1 from the ketone solution was demonstrated at 89% yield, >99% purity, and 22 g h−1 production rates using MSMPRs in series for 18 hours total flow time. Key benefits to this continuous approach include greater than 30% reduced process mass intensity and magnesium usage relative to a traditional batch process. In addition, the flow process imparts significant process safety benefits for Barbier/Grignard processes including >100× less excess magnesium to quench, >100× less diisobutylaluminum hydride to initiate, and in this system, maximum long-term scale is expected to be 50 L which replaces 4000–6000 L batch reactors.
Journal of Organic Chemistry | 2013
Catherine N. Slattery; Rebecca E. Deasy; Anita R. Maguire; Michael E. Kopach; Utpal K. Singh; Mark D. Argentine; William George Trankle; Roger B. Scherer; Humphrey A. Moynihan
An efficient synthetic approach leading to introduction of the hydroxymethyl group to an aryl moiety via combination of the Bouveault formylation and hydride reduction has been optimized using a rational, mechanistic-based approach. This approach enabled telescoping of the two steps into a single efficient process, readily amenable to scaleup.
Green Chemistry | 2018
Frank Roschangar; Yanyan Zhou; David J.C. Constable; Juan Colberg; David P. Dickson; Peter J. Dunn; Martin D. Eastgate; Fabrice Gallou; John D. Hayler; Stefan G. Koenig; Michael E. Kopach; David K. Leahy; Ingrid Mergelsberg; Ulrich Scholz; Austin G. Smith; Manuel Henry; Jason A. Mulder; Jörg Brandenburg; Juan R. Dehli; Daniel R. Fandrick; Keith R. Fandrick; Frieder Gnad-Badouin; Georg Zerban; Klaus Groll; Paul T. Anastas; Roger A. Sheldon; Chris H. Senanayake
Following our goal to devise a unified green chemistry metric that inspires innovation in sustainable drug manufacturing across the pharmaceutical industry, we herein disclose joint efforts by IQ, the ACS GCI PR and academia, leading to the significantly improved ‘innovation Green Aspiration Level’ (iGAL) methodology. Backed by the statistical analysis of 64 drug manufacturing processes encompassing 703 steps across 12 companies, we find that iGAL affords an excellent proxy for molecular complexity and presents a valuable molecular weight-based ‘fixed’ goal. iGAL thereby accurately captures the impact of green process inventiveness and improvements, making it a useful innovation-driven green metric. We conclude by introducing the comprehensive, yet easy-to-use and readily adaptable Green Chemistry Innovation Scorecard web calculator, whose graphical output clearly and effectively illustrates the impact of innovation on waste reduction during drug manufacture.
Journal of Pharmaceutical Sciences | 2017
Cherokee S. Hoaglund Hyzer; Michele L. Williamson; Patrick J. Jansen; Michael E. Kopach; R. Brian Scherer; Steven W. Baertschi
Edivoxetine (LY2216684 HCl), although a chemically stable drug substance, has shown the tendency to degrade in the presence of carbohydrates that are commonly used tablet excipients, especially at high excipient:drug ratios. The major degradation product has been identified as N-formyl edivoxetine. Experimental evidence including solution and solid-state investigations, is consistent with the N-formylation degradation pathway resulting from a direct reaction of edivoxetine with (1) formic acid (generated from decomposition of microcrystalline cellulose or residual glucose) and (2) the reducing sugar ends (aldehydic carbons) of either residual glucose or the microcrystalline cellulose polymer. Results of labeling experiments indicate that the primary source of the formyl group is the C1 position from reducing sugars. Presence of water or moisture accelerates this degradation pathway. Investigations in solid and solution states support that the glucose Amadori Rearrangement Product does not appear to be a direct intermediate leading to N-formyl degradation of edivoxetine, and oxygen does not appear to play a significant role. Solution-phase studies, developed to rapidly assess propensity of amines toward Maillard reactivity and formylation, were extended to show comparative behavior with example systems. The cyclic amine systems, such as edivoxetine, showed the highest propensity toward these side reactions.
Organic Process Research & Development | 2009
Michael E. Kopach; Michael M. Murray; Timothy M. Braden; Michael E. Kobierski; Otis L. Williams
Journal of the American Chemical Society | 1996
Michael E. Kopach; and Andrew H. Fray; A. I. Meyers
Organic Process Research & Development | 2007
William George Trankle; Michael E. Kopach
Organic Process Research & Development | 2013
David K. Leahy; John L. Tucker; Ingrid Mergelsberg; Peter J. Dunn; Michael E. Kopach; Vikram C. Purohit